Law360, New York (November 04, 2009) -- The U.S. Patent and Trademark Office recently announced that it is rescinding its highly controversial new patent rules and that a motion to dismiss and vacate the district court decision on these regulations litigated in Tafas v. Dudas (now Tafas v. Kappos) will be filed jointly with one of the plaintiffs-appellees, GlaxoSmithKline (GSK).[1]
According to the new director of the USPTO, David Kappos, the rationale for rescinding these regulations is that “(t)he USPTO should incentivize innovation, develop rules that are responsive to its...
